Deutsch
 
Hilfe Datenschutzhinweis Impressum
  DetailsucheBrowse

Datensatz

 
 
DownloadE-Mail
  B cells and antibodies in multiple sclerosis pathogenesis and therapy

Krumbholz, M., Derfuss, T., Hohlfeld, R., & Meinl, E. (2012). B cells and antibodies in multiple sclerosis pathogenesis and therapy. NATURE REVIEWS NEUROLOGY, 8(11), 613-623. doi:10.1038/nrneurol.2012.203.

Item is

Externe Referenzen

einblenden:

Urheber

einblenden:
ausblenden:
 Urheber:
Krumbholz, Markus1, Autor           
Derfuss, Tobias2, Autor           
Hohlfeld, Reinhard1, Autor           
Meinl, Edgar1, Autor           
Affiliations:
1Department: Neuroimmunology / Wekerle, MPI of Neurobiology, Max Planck Society, ou_1113547              
2external, ou_persistent22              

Inhalt

einblenden:
ausblenden:
Schlagwörter: CENTRAL-NERVOUS-SYSTEM; RITUXIMAB-TREATED PATIENTS; AUTOREACTIVE PLASMA-CELLS; BLOOD MONONUCLEAR-CELLS; CEREBROSPINAL-FLUID; NEUROMYELITIS-OPTICA; RHEUMATOID-ARTHRITIS; LUPUS-ERYTHEMATOSUS; CORTICAL DEMYELINATION; DISEASE PROGRESSION
 Zusammenfassung: B cells and antibodies account for the most prominent immunodiagnostic feature in patients with multiple sclerosis (MS), namely oligoclonal bands. Furthermore, evidence is accumulating that B cells and antibodies contribute to MS pathogenesis in at least a subset of patients. The CNS provides a B-cell-fostering environment that includes B-cell trophic factors such as BAFF (B-cell-activating factor of the TNF family), APRIL (a proliferation-inducing ligand), and the plasma-cell survival factor CXCL12. Owing to this environment, the CNS of patients with MS is not only the target of the immunopathological process, but also becomes the site of local antibody production. B cells can increase or dampen CNS inflammation, but their proinflammatory effects seem to be more prominent in most patients, as B-cell depletion is a promising therapeutic strategy. Other therapies not primarily designed to target B cells have numerous effects on the B-cell compartment. This Review summarizes key features of B-cell biology, the role of B cells and antibodies in CNS inflammation, and current attempts to identify the targets of pathogenic antibodies in MS. We also review the effects of approved and investigational interventions-including CD20-depleting antibodies, BAFF/APRIL-depleting agents, alemtuzumab, natalizumab, FTY720, IFN-beta, glatiramer acetate, steroids and plasma exchange-on B-cell immunology.

Details

einblenden:
ausblenden:
Sprache(n): eng - English
 Datum: 2012-11
 Publikationsstatus: Erschienen
 Seiten: 11
 Ort, Verlag, Ausgabe: -
 Inhaltsverzeichnis: -
 Art der Begutachtung: Expertenbegutachtung
 Identifikatoren: ISI: 000310774100007
DOI: 10.1038/nrneurol.2012.203
 Art des Abschluß: -

Veranstaltung

einblenden:

Entscheidung

einblenden:

Projektinformation

einblenden:

Quelle 1

einblenden:
ausblenden:
Titel: NATURE REVIEWS NEUROLOGY
Genre der Quelle: Zeitschrift
 Urheber:
Affiliations:
Ort, Verlag, Ausgabe: 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA : NATURE PUBLISHING GROUP
Seiten: - Band / Heft: 8 (11) Artikelnummer: - Start- / Endseite: 613 - 623 Identifikator: ISSN: 1759-4758